Specialist Chapter: Trends and Strategies in Global Pharma and Biotech Patent Litigation
IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.
Stay updated with breaking news from Patent Interference. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.
U.S. courts will have a full docket of challenging IP cases throughout 2023. Andy Warhol Found. for Visual Arts, Inc. v. Goldsmith, Amgen Inc. v. Sanofi, Interactive Wearables, LLC v. Polar Electro Oy et al., VIP Prods. LLC v. Jack Daniel's Props., Nike, Inc. v. StockX LLC.
With the continuing advancements of cutting-edge technologies — such as genome editing (CRISPR) and Non-Fungible Tokens (NFTs) — U.S. courts will have a full docket of challenging IP...
Is the genus claim dead, or has its demise been greatly exaggerated? We may soon have the Supreme Court’s answer. On April 18, following eight years…
Companies have been exploring the potential to use combinations of various checkpoint inhibitors to enhance the treatment of patients with various…